Methods and compositions for delivering immunotherapeutic agents that cross the blood-brain barrier to treat brain tumors

Abstract

This application relates to sequences that enhance penetration of immunotherapeutic agents across the blood-brain barrier, compositions comprising the sequences, and methods of use thereof for treating brain tumors, such as glioblastoma (GBM).

Description

[Technical Field]

[0001] Claim of priority This application claims the benefits of U.S. Provisional Patent Application No. 62 / 959,625, filed on January 10, 2020. The entirety of the foregoing is incorporated herein by reference.

[0002] Sequences that enhance the penetration of immunotherapeutic agents across the blood-brain barrier, compositions comprising such sequences, and methods of use thereof for treating brain tumors, such as glioblastoma (GBM), are described herein. [Background technology]

[0003] Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults, with a median overall survival of only 15 months. 1 Approximately 12,000 new cases of GBM are diagnosed annually in the United States, with an incidence rate of 3.2 per 100,000 people. 2 Despite significant progress in understanding the histology, molecular landscape, and tumor microenvironment of GBM, 3~6 Since 2005, there has been little progress in treatment. One major obstacle to translating the inventors' extensive knowledge of GBM into effective treatment is inefficient drug delivery to GBM tumor sites. GBM tumors are structurally well angiogenic. 7 Intravenous administration is, in theory, a convenient and widely applicable route of drug delivery that can achieve a good tumor coverage. However, designing drugs to cross the blood-brain barrier (BBB) ​​and / or the blood-oncological barrier remains challenging. [Overview of the Initiative]

[0004] Glioblastoma is a highly fatal brain tumor that is difficult to treat using conventional methods. Systemic delivery of cancer gene therapy represents a new therapeutic paradigm for tackling glioblastoma. Engineered brain-permeable AAV virus vectors are described herein to establish an intravascular gene delivery platform for glioblastoma gene therapy, for example, to deliver a PD-L1 antibody systemically for the treatment of glioblastoma.

[0005] Accordingly, a method for delivering an immunotherapy agent to cancer in a subject is provided herein. The method comprises the step of administering an adeno-associated virus (AAV) to a subject, which comprises (i) a capsid protein comprising an amino acid sequence containing at least four consecutive amino acids from the sequence TVSALFK (SEQ ID NO: 8); TVSALK (SEQ ID NO: 4); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84); and (ii) a transgene encoding an immunotherapy agent, wherein the cancer cells are optionally located in the brain of the human subject.

[0006] In some embodiments, the amino acid sequence includes at least five consecutive amino acids from the sequence TVSALK (SEQ ID NO: 4); TVSALFK (SEQ ID NO: 8); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84).

[0007] In some embodiments, the amino acid sequence includes at least six consecutive amino acids from the sequence TVSALK (SEQ ID NO: 4); TVSALFK (SEQ ID NO: 8); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84).

[0008] Also provided herein is a method for delivering an immunotherapy agent to cancer in a subject. This method comprises the step of administering an adeno-associated virus (AAV) to a subject, which optionally includes cancer cells in the brain of a human subject, comprising (i) a capsid protein comprising an amino acid sequence containing at least four consecutive amino acids from sequence V[S / p][A / m / t / ]L (SEQ ID NO: 79), TV[S / p][A / m / t / ]LL (SEQ ID NO: 80), TV[S / p][A / m / t / ]LK (SEQ ID NO: 81), or TV[S / p][A / m / t / ]LFK (SEQ ID NO: 82), and (ii) a transgene encoding an immunotherapy agent, wherein cancer cells are optionally present in the brain of the human subject.

[0009] In some embodiments, the targeting sequence includes VPALR (sequence number 1); VSALK (sequence number 2); TVPALR (sequence number 3); TVSALK (sequence number 4); TVPMLK (sequence number 12); TVPTLK (sequence number 13); FTVSALK (sequence number 5); LTVSALK (sequence number 6); TVSALFK (sequence number 8); TVPALFR (sequence number 9); TVPMLFK (sequence number 10) or TVPTLFK (sequence number 11).

[0010] In some embodiments, the transgene encoding the immunotherapy agent encodes an antibody that targets PD-1 or PD-L1.

[0011] In some embodiments, the subjects are mammals.

[0012] In some embodiments, the AAV is the AAV9.

[0013] In some embodiments, the AAV9 includes the AAV9 VP1.

[0014] In some embodiments, the targeting sequence is inserted at positions corresponding to amino acids 588 and 589 of AAV9 VP1, including SEQ ID NO: 85.

[0015] In some embodiments, the cells are located within the target brain, and AAV is administered by parenteral delivery, intracerebral delivery, or intrathecal delivery.

[0016] In some embodiments, parenteral delivery is by intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular delivery.

[0017] In some embodiments, intrathecal delivery is performed by lumbar injection, cisterna magna injection, or intraparenchymal injection.

[0018] In some embodiments, the method further includes the step of administering a chemotherapeutic agent, radiation, and / or surgical resection.

[0019] In some embodiments, the chemotherapeutic agent includes temozolamide, lomustine, or a combination thereof.

[0020] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the present invention pertains. Methods and materials are described herein for use in the present invention, and other suitable methods and materials known in the art may also be used. Materials, methods, and examples are illustrative and not intended to limit the scope. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of any conflict, including definitions, this specification shall prevail.

[0021] Other features and advantages of the present invention will become apparent from the following detailed description and drawings, as well as from the claims. [Brief explanation of the drawing]

[0022] [Figure 1-1]Figures 1A-1C: Illustrative strategies for engineering AAV9 by inserting a cell-penetrating peptide (CPP) into its capsid. Figure 1A is a 3D model of the AAV9 virus. The individual CPP inserted into the capsid between amino acids 588 and 589 (VP1 numbering) is shown at the three-fold axis where receptor binding likely occurs. Figure 1B illustrates the method for producing individual AAVs. Three plasmids, pRC (engineered or not), p helper, and pAAV, are co-transfected into HEK 293T cells, and AAV is recovered and purified using an iodixanol gradient. Figure 1C is a vector diagram of an illustrative vector containing a sequence encoding an anti-PDL1 antibody. [Figure 1-2] (As described above.) [Figure 2-1] Figures 2A-2B: Representative images (Figure 2A) and their quantitative analysis (Figure 2B) of mouse brain sections after intravenous administration of low doses of candidate AAVs. Mice with a mixed genetic background are used. The candidate AAVs all express nuclear red fluorescent protein (RFP) as a reporter, although their inserted CPPs are different (see Table 3). Candidate AAVs with low production yields are excluded for further screening. The dose of AAV is 1×1010 vg (viral genome) per animal. Each white dot in Figure 2A represents an RFP-labeled cell. In Figure 2B, *p<0.05, ANOVA, compared to AAV9. [Figure 2-2] (As described above.) [Figure 2-3]Figures 2C-2D: Representative images (Figure 2C) and their quantitative analysis (Figure 2D) of mouse brain sections after intravenous administration of AAV.CPP.11 and AAV.CPP.12 in repeated experiments. AAV.CPP.11 and AAV.CPP.12 contain CPP BIP1 and BIP2, respectively (see Table 3). The dose of AAV was increased up to 1×1011 vg per animal. The candidate AAV expresses nuclear red fluorescent protein (RFP) as a reporter. Each white dot in Figure 2C represents an RFP-labeled cell. In Figure 2D, *P<0.05, **P<0.01, ANOVA versus AAV9. [Figure 2-4] (As described above.) [Figure 3-1] Figure 3A: Diagram showing the optimization of the BIP targeting sequence for further engineering of AAV9 for better brain transduction. BIP1 (VPALR, SEQ ID NO: 1), which enables more efficient transduction of the brain (like AAV.CPP.11), is derived from the protein Ku70 in rats. The Ku70 proteins of humans, mice, and rats differ in their exact amino acid sequences. BIP2 (VSALK, SEQ ID NO: 2), like AAV.CPP.12, is a "synthetic" peptide related to BIP1. Desiring to minimize the species specificity of the final engineered AAV, further engineering focuses on the VSALK sequence. To generate new targeting sequences, the amino acids of interest are added to the VSALK sequence and, in other cases, the positions of individual amino acids are switched. All new BIP2-derived sequences are reinserted into the AAV9 capsid to generate new candidate AAVs for screening. The sequences listed in order are SEQ ID NOs: 69, 70, 71, 1-6, 72, 7, and 8. [Figure 3-2]Figures 3B-3C: This figure shows representative images (Figure 3B) of mouse brain sections after intravenous administration of multiple candidate AAVs and their quantitative analysis (Figure 3C). All candidate AAVs express nuclear red fluorescent protein (RFP) as a reporter. The dose of AAV is 1 × 10¹¹ vg per animal. Each white dot in Figure 3B represents an RFP-labeled cell. AAV.CPP.16 and AAV.CPP.21 were identified as top hits with robust and widespread brain transduction. In Figure 3C, for AAV9, *P<0.05, **P<0.01, ***P<0.001, ANOVA. Figure 3D: This figure shows a quantitative analysis of transduction efficiency in the liver after intravenous administration of candidate AAVs. It represents the percentage of transduced hepatocytes. The dose of AAV is 1 × 10¹¹ vg per animal. For AAV9, ***P<0.001, ANOVA. [Figure 3-3] (As stated above.) [Figure 4-1] Figures 4A-4E: These figures show the screening of selected candidate AAVs in an in vitro spheroid model of the human blood-brain barrier. Figure 4A illustrates a spheroid containing human microvascular endothelial cells that form the barrier on its surface, as well as human pericytes and astrocytes inside the spheroid. Candidate AAVs were evaluated for their ability to permeate from the surrounding culture medium into the interior of the spheroid and transduce cells within. Figures 4B-4D show images of spheroids treated with AAV9 (Figure 4B), AAV.CPP.16 (Figure 4C), and AAV.CPP.21 (Figure 4D). Figure 4E shows the relative RFP intensity of spheroids treated with different AAVs. ***P<0.001, ANOVA, relative to AAV9. [Figure 4-2] (As stated above.) [Figure 4-3] (As stated above.) [Figure 5-1]Figures 5A-5B: These figures show representative images (Figure 5A) and quantitative analyses (Figure 5B) of brain sections after intravenous administration of AAV9, AAV.CPP.16, and AAV.CPP.21 in C57BL / 6J inbred mice. All candidate AAVs express nuclear red fluorescent protein (RFP) as a reporter. The AAV dose is 1 × 10¹² vg per animal. Each white dot in Figure 5A represents an RFP-labeled cell. In Figure 5B, *P<0.05, ***P<0.001, ANOVA. [Figure 5-2] (As stated above.) [Figure 6-1] Figures 6A-6B: These figures show representative images (Figure 6A) and quantitative analyses (Figure 6B) of brain sections after intravenous administration of AAV9, AAV.CPP.16, and AAV.CPP.21 in BALB / cJ inbred mice. All candidate AAVs express nuclear red fluorescent protein (RFP) as a reporter. The AAV dose is 1 × 10¹² vg per animal. Each white dot in Figure 6A represents an RFP-labeled cell. In Figure 6B, ***P<0.001, ANOVA. [Figure 6-2] (As stated above.) [Figure 7-1] Figures 7A-7B: These figures show representative images (Figure 7A) and quantitative analyses (Figure 7B) of brain sections after intravenous administration of high doses of AAV.CPP.16 and AAV.CPP.21 in C57BL / 6J inbred mice. Both candidate AAVs express nuclear red fluorescent protein (RFP) as a reporter. The dose of AAV is 4 × 10¹² vg per animal. Each white dot in Figure 7A represents an RFP-labeled cell. In Figure 7B, *P<0.05, Student's test. [Figure 7-2] (As stated above.) [Figure 8-1]Figure 8A: This figure shows that AAV.CPP.16 and AAV.CPP.21 transduce mature neurons (labeled with NeuN antibody) across multiple brain regions in mice, including the cerebral cortex, midbrain, and hippocampus. Transduced neurons were co-labeled with NeuN antibody and RFP. 4 × 10¹² vg of AAV was administered intravenously to adult C57BL / 6J mice (6 weeks old). [Figure 8-2] (As stated above.) [Figure 8-3] Figure 8B: This figure shows that AAV.CPP.16 and AAV.CPP.21 exhibit enhanced ability compared to AAV9 in targeting spinal cord and motor neurons in mice. 4 × 10¹⁰ vg of AAV was administered intravenously to neonatal mice (1 day postnatal). Motor neurons in the anterior horn of the spinal cord were visualized using CHAT antibody staining. Co-localization of RFP and CHAT signals suggests specific transduction of motor neurons. [Figure 9-1] Figure 9A: This figure shows that AAV.CPP.16 exhibits enhanced ability compared to AAV9 in cardiac targeting in adult mice. 1 × 10¹¹ vg of AAV was administered intravenously to adult C57BL / 6J mice (6 weeks old). The percentage represents the ratio of RFP-labeled cells to all DAPI-stained cells. *P<0.05, Student's test. [Figure 9-2] Figure 9B: This figure shows that AAV.CPP.16 exhibits enhanced ability compared to AAV9 in targeting skeletal muscle in adult mice. 1 × 10¹¹ vg of AAV was administered intravenously to adult C57BL / 6J mice (6 weeks old). The percentage represents the ratio of RFP-labeled cells to all DAPI-stained cells. *P<0.05, Student's test. [Figure 9-3] Figure 9C: This figure shows that AAV.CPP.16 exhibits enhanced ability compared to AAV9 in targeting the dorsal root ganglia (DRG) in adult mice. 1 × 10¹¹ vg of AAV was administered intravenously to adult C57BL / 6J mice (6 weeks old). The percentage represents the ratio of RFP-labeled cells to all DAPI-stained cells. *P<0.05, Student's test. [Figure 10-1] Figure 10A: This figure shows that AAV.CPP.16 and AAV.CPP.21 exhibit enhanced ability to transduce brain cells in the primary visual cortex in non-human primates after intravenous administration, compared to AAV9. 2 × 10¹³ vg / kg of AAV-CAG-AADC (as a reporter gene) was intravenously injected into 3-month-old cynomolgus monkeys with low levels of pre-existing neutralizing antibodies. AAV-transduced cells (shown in black) were visualized using antibody staining against AADC. The square regions in the left panel are enlarged as shown in the right panel. AAV.CPP.16 transduced significantly more cells than AAV9. AAV.CPP.21 also transduced more cells than AAV9, but its effect was less pronounced compared to AAV.CPP.16. [Figure 10-2] Figure 10B: This figure shows that AAV.CPP.16 and AAV.CPP.21 exhibit enhanced ability to transduce brain cells in the parietal cortex of non-human primates after intravenous administration, compared to AAV9. 2 × 10¹³ vg / kg of AAV-CAG-AADC (as a reporter gene) was intravenously injected into 3-month-old cynomolgus monkeys with low levels of pre-existing neutralizing antibodies. AAV-transduced cells (shown in black) were visualized using antibody staining against AADC. The square regions in the left panel are enlarged as shown in the right panel. AAV.CPP.16 transduced significantly more cells than AAV9. AAV.CPP.21 also transduced more cells than AAV9, but its effect was less pronounced compared to AAV.CPP.16. [Figure 10-3]Figure 10C: This figure shows that AAV.CPP.16 and AAV.CPP.21 exhibit enhanced ability to transduce brain cells in the thalamus of non-human primates after intravenous administration, compared to AAV9. 2 × 10¹³ vg / kg of AAV-CAG-AADC (as a reporter gene) was intravenously injected into 3-month-old cynomolgus monkeys with low levels of pre-existing neutralizing antibodies. AAV-transduced cells (shown in black) were visualized using antibody staining against AADC. The square regions in the left panel are enlarged as shown in the right panel. AAV.CPP.16 transduced significantly more cells than AAV9. AAV.CPP.21 also transduced more cells than AAV9, but its effect was less pronounced compared to AAV.CPP.16. [Figure 10-4] Figure 10D: This figure shows that AAV.CPP.16 and AAV.CPP.21 exhibit enhanced ability compared to AAV9 to transduce brain cells in the cerebellum after intravenous administration in non-human primates. 2 × 10¹³ vg / kg of AAV-CAG-AADC (as a reporter gene) was intravenously injected into 3-month-old cynomolgus monkeys with low levels of pre-existing neutralizing antibodies. AAV-transduced cells (shown in black) were visualized using antibody staining against AADC. The square region in the left panel is enlarged as shown in the right panel. Both AAV.CPP.16 and AAV.CPP.21 transduce significantly more cells than AAV9. [Figure 11]Figures 11A-11B show that AAV.CPP.16 and AAV.CPP.21 do not bind to LY6A. LY6A acts as a receptor for AAV.PHP.B and its variants, including AAV.PHP.eB (as described in U.S. Patent No. 9102949 and U.S. Patent Application Publication No. 20170166926), and mediates the robust effect of AAV.PHP.eB when crossing the blood-brain barrier (Hordeaux et al. Mol Ther 2019 27(5):912-921; Huang et al. 2019, dx.doi.org / 10.1101 / 538421). Overexpression of mouse LY6A in 293 cultured cells significantly increases the binding of AAV.PHP.eB to the cell surface (Figure 11A). In contrast, overexpression of LY6A did not increase viral binding to AAV9, AAV.CPP.16, or AAV.CPP.21 (Figure 11B). This suggests that AAV.CPP.16 or AAV.CPP.21 do not share LY6A as a receptor with AAV.PHP.eB. [Figure 12-1] Figures 12A-12C: These figures show that AAV.CPP.21 can be used to systemically deliver therapeutic genes to brain tumors in a mouse-like manner with glioblastoma (GBM). As shown in Figure 11A, intravenously administered AAV.CPP.21-H2BmCherry showed targeting of the tumor, particularly the tumor's spreading frontier (Figure 12A). In Figures 11B (image) and 11C (quantitative analysis), using AAV.CPP.21 to systemically deliver the “suicide gene” HSV.TK1, when combined with the prodrug ganciclovir, resulted in brain tumor reduction. HSV.TK1 converts ganciclovir, which is otherwise “dormant,” into a tumor killer. *P<0.05, Student’s test. [Figure 12-2] (As stated above.) [Figure 12-3] (As stated above.) [Figure 13-1]This figure shows that when AAV.CPP.21 was injected locally into the brains of adult mice, it produced more extensive and robust transduction of brain tissue compared to AAV9. Adult mice (>6 weeks old) were injected intracerebrally with AAV (1 × 10¹¹vg), and brain tissue was collected and examined 3 weeks after AAV injection. **P<0.01, Student's test. [Figure 13-2] (As stated above.) [Figure 14] Figure 14: A set of images comparing the delivery efficiency to the GBM tumor microenvironment in mouse models using AAV9 (top) and AAV.CPP16 (bottom). As can be seen in the inset (right), AAV.CPP16 provided a superior delivery effect. [Figure 15-1] Figures 15A-C show that AAV.CPP.16 anti-PD-L1 mediated immunotherapy extended survival time in a mouse GBM model. Figure 15A: Outline of the experimental protocol. Figure 15B: Survival time of animals treated as shown. Figure 15C: Long-term survival time of animals treated with AAV.CPP16-anti-PD-L1. LTS: Long-term survival time. [Figure 15-2] (As stated above.) [Figure 16-1] Figures 16A-C: These figures show that GBM tumors were eradicated in all long-term surviving mice. Figure 16A: H&E staining of both posterior and anterior brain sections at the tumor injection site. No residual GBM is present in any section. Figure 16B: Bioluminescence imaging 7 days after tumor transplantation, suggesting the success of the initial tumor transplant. Figure 16C: GBM tumor transplantation site with scar tissue. [Figure 16-2] (As stated above.) [Figure 17-1] Figures 17A-17B show the expression of HA-tagged anti-PD-L1 antibodies in GBM tumors as measured by Western blotting. 1e12vg of AAV or PBS was intravenously injected into mice 5 days after tumor transplantation. Tumor tissue was collected 14 days after IV injection. The intensity of HA tag staining (Figure 17A) was quantified as a measure of anti-PD-L1 antibody expression (Figure 17B). [Figure 17-2] (As stated above.) [Modes for carrying out the invention]

[0023] Difficulties associated with cross-barbin (BBB) ​​delivery have hindered the development of therapeutic agents to treat brain disorders, including cancer. Adeno-associated viruses (AAVs) have emerged as a key research and clinical tool for delivering therapeutic genes to the brain, spinal cord, and eyes. See, for example, U.S. Patent No. 9,102,949; U.S. Patent No. 9,585,971; and U.S. Patent Publication No. 2017,0166,926. AAV-mediated gene therapy has made significant progress with the recent approvals of Luxturna and Zolgensma. The approval of Zolgensma for endovascular treatment in patients with spinal muscular atrophy under two years of age is particularly promising because it demonstrates the feasibility of using AAV vectors across the BBB for systemic gene therapy of the central nervous system (CNS). Despite its success in young patients, AAV9, the AAV serotype used in Zolgensma, suffers from low efficiency across the BBB, particularly in adults, limiting its application to other CNS diseases. 8、9 A next-generation brain-penetrating AAV vector (i.e., AAV.CPP16) is described herein, which achieves at least 5–10 times enhancement over the current industry standard (i.e., AAV9) in both rodents and non-human primates and may be used for a novel BBB-crossing AAV platform for GBM oncogene therapy.

[0024] Through rational design and targeting screening based on known cell-permeable peptides (CPPs) (see, e.g., Gomez et al., Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. Biochem. Soc. Trans. 2007;35(Pt 4):797-801), targeted sequences have been discovered that, when engineered into AAV capsids, improve the efficiency of gene delivery to the brain by up to three orders of magnitude. These methods have been used to engineer AAV vectors that dramatically reduce tumor size in animal models of glioblastoma.

[0025] Furthermore, the brain possesses "immune privileges" that make immunotherapy for GBM challenging. It is desirable to "prime" the immune response to transform immunologically "cold" GBM tumors into immunogenic "hot" GBM tumors. This method uses the vector described herein to deliver an immunotherapeutic agent, such as an anti-PD-L1 antibody, which can achieve precisely this. While we do not wish to be bound by theory, the AAV vector itself "primes" the immune system by increasing tumor infiltration of cytotoxic T cells, but the anti-PD-L1 antibody expressed at the tumor site and in the CNS as a whole is thought to activate "depleted" T cells in other ways.

[0026] Targeted sequence This method identified several potential targeted peptides that, when inserted into the capsid of AAVs, such as AAV1, AAV2, AAV8, or AAV9, or when conjugated to biological factors, such as antibodies or other large biomolecules, either chemically or through expression as fusion proteins, enhance blood-brain barrier (BBB) ​​permeability.

[0027] In some embodiments, the targeted peptide comprises a sequence of at least five amino acids. In some embodiments, the amino acid sequence comprises at least four consecutive amino acids, for example, five consecutive amino acids in the sequences VPALR (SEQ ID NO: 1) and VSARK (SEQ ID NO: 2).

[0028] In some embodiments, the targeted peptide includes the sequence X1X2X3X4X5, (i) X1, X2, X3, X4 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (ii) X5 is K, R, H, D, or E (Sequence ID 73).

[0029] In some embodiments, the targeted peptide comprises a sequence of at least six amino acids. In some embodiments, the amino acid sequence comprises at least four, for example, five or six consecutive amino acids in the sequences TVPALR (SEQ ID NO: 3), TVSALK (SEQ ID NO: 4), TVPMLK (SEQ ID NO: 12), and TVPTLK (SEQ ID NO: 13).

[0030] In some embodiments, the targeted peptide includes the sequence X1X2X3X4X5X6, (i) X1 is T, (ii) X2X3X4X5 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (iii) X6 is K, R, H, D, or E (Sequence ID 74).

[0031] In some embodiments, the targeted peptide includes the sequence X1X2X3X4X5X6, (i) X1X2X3X4 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (ii) X5 is K, R, H, D, or E, (iii) X6 is either E or D (Sequence ID 75).

[0032] In some embodiments, the targeted peptide comprises a sequence of at least seven amino acids. In some embodiments, the amino acid sequence comprises at least four, for example, five, six, or seven consecutive amino acids in the sequence FTVSALK (SEQ ID NO: 5), LTVSALK (SEQ ID NO: 6), TVSALFK (SEQ ID NO: 8), TVPALFR (SEQ ID NO: 9), TVPMLFK (SEQ ID NO: 10), and TVPTLFK (SEQ ID NO: 11). In some other embodiments, the targeted peptide comprises the sequence X1X2X3X4X5X6X7. (i) X1 is F, L, W, or Y, (ii) X2 is T, (iii) X3, X4, X5, X6 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (iv) X7 is K, R, H, D, or E (Sequence ID 76).

[0033] In some embodiments, the targeted peptide includes the sequence X1X2X3X4X5X6X7, (i) X1 is T, (ii) X2, X3, X4, and X5 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (iii) X6 is K, R, H, D, or E, (iv) X7 is either E or D (Sequence ID 77).

[0034] In some embodiments, the targeted peptide includes the sequence X1X2X3X4X5X6X7, (i) X1, X2, X3, X4 are any four non-identical amino acids from V, A, L, I, G, P, S, T, or M, (ii) X5 is K, R, H, D, or E, (iii) X6 is either E or D, (iv) X7 is either A or I (Sequence ID 78).

[0035] In some embodiments, the targeted peptide comprises the sequence V[S / p][A / m / t / ]L (SEQ ID NO: 79), where the capital letter is preferred. In some embodiments, the targeted peptide comprises the sequence TV[S / p][A / m / t / ]L (SEQ ID NO: 80). In some embodiments, the targeted peptide comprises the sequence TV[S / p][A / m / t / ]LK (SEQ ID NO: 81). In some embodiments, the targeted peptide comprises the sequence TV[S / p][A / m / t / ]LFK (SEQ ID NO: 82).

[0036] In some embodiments, the targeted peptide is not VPALR (SEQ ID NO: 1) or VSARK (SEQ ID NO: 2).

[0037] Specific example amino acid sequences containing the five, six, or seven amino acid sequences mentioned above are listed in Table 1.

[0038] [Table 1-1]

[0039] [Table 1-2]

[0040] Targeted peptides containing inverted sequences, such as KLASVT (SEQ ID NO: 83) and KFLASVT (SEQ ID NO: 84), may also be used.

[0041] The targeted peptides disclosed herein may be modified according to methods known in the art for producing peptide mimes. For example, Qvit et al., Drug Discov Today. 2017 Feb; 22(2): 454-462; Farhadi and Hashemian, Drug Des Devel Ther. 2018; 12: 1239-1254; Avan et al., Chem. Soc. Rev., 2014,43, 3575-3594; Pathak, et al., Indo American Journal of Pharmaceutical Research, 2015. 8; Kazmierski, WM, ed., Peptidomimetics Protocols, Human Press (Totowa NJ 1998); Goodman et al., eds., Houben-Weyl Methods of Organic Chemistry: Synthesis of Peptides and Peptidomimetics, Thiele Verlag (New York 2003); and Mayo et al., J. Biol. Chem., 278:45746 See (2003). In some cases, these modified peptide mimetic forms of the peptides and fragments disclosed herein exhibit enhanced in vivo stability compared to non-peptide mimetic peptides.

[0042] A method for producing a peptide mime is to substitute one or more, for example, all, amino acids in a peptide sequence with a D-amino acid enantiomer. Such a sequence is referred to herein as a “retro” sequence. In another method, the N-terminus to C-terminus order of amino acid residues is reversed such that the N-terminus to C-terminus order of amino acid residues in the original peptide becomes the C-terminus to N-terminus order in the modified peptide mime. Such a sequence may be referred to as an “inverso” sequence.

[0043] Peptide mimes can be of both retro and inverso forms, i.e., the “retro-inverso” form of the peptides disclosed herein. Novel peptide mimes may consist of D amino acids arranged such that the order of amino acid residues from the N-terminus to the C-terminus in the peptide mime is the same as the order of amino acid residues from the C-terminus to the N-terminus in the original peptide.

[0044] Other methods for producing peptide mimes include replacing one or more amino acid residues in a peptide with chemically different but recognized functional analogues of amino acids, i.e., artificial amino acid analogues. Artificial amino acid analogues include β-amino acids, β-substituted β-amino acids ("β"). 3 This includes amino acids, phosphite analogs of amino acids such as ∀-aminophosphonic acid and ∀-aminophosphinic acid, and amino acids having non-peptide bonds. Artificial amino acids can be used to create peptide mimes such as peptoid oligomers (e.g., peptoid amides or ester analogs), β-peptides, cyclic peptides, oligoureas or oligocarbamate peptides; or heterocyclic molecules. Exemplary retro-inverso-targeted peptide mimes include KLASVT and KFLASVT, whose sequences contain all D amino acids. These sequences can be modified, for example, by biotinylation of the amino terminology and amidation of the carboxyl terminology.

[0045] AAV Viral vectors for use in this method and composition include recombinant retroviruses, adenoviruses, adeno-associated viruses, alphaviruses, and lentiviruses, which include the targeted peptides described herein and, optionally, the transgene for expression in the target tissue.

[0046] A preferred viral vector system useful for nucleic acid delivery in this method is adeno-associated virus (AAV). AAV is a small, non-enveloped virus with a 25 nm capsid. No diseases associated with wild-type AAV are known or have not been demonstrated. AAV has a single-stranded DNA (ssDNA) genome. AAV has been shown to exhibit long-term episomal transgene expression, and has demonstrated excellent transgene expression in the brain, particularly in nerve cells. Vectors containing as little as 300 base pairs of AAV can be packaged and incorporated. The space for exogenous DNA is limited to approximately 4.7 kb. AAV vectors, such as those described in Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985), can be used to introduce DNA into cells. Various nucleic acids have been introduced into different cell types using AAV vectors (see, for example, Hermonat et al., Proc. Natl. Acad. Sci. USA 81:6466-6470 (1984); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1985); Wondisford et al., Mol. Endocrinol. 2:32-39 (1988); Tratschin et al., J. Virol. 51:611-619 (1984); and Flotte et al., J. Biol. Chem. 268:3781-3790 (1993)). Many alternative AAV variants exist (over 100 have been cloned), and these variants are identified based on desired features. In some embodiments, the AAV is AAV1, AAV2, AAV4, AAV5, AAV6, AV6.2, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43, or CSp3; for use in the CNS, in some embodiments, the AAV is AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, or AAV9. As an example, AAV9 has been shown to cross the blood-brain barrier with some efficiency.Using this method, AAV capsids can be genetically engineered to increase their ability to cross the blood-brain barrier (BBB) ​​or penetrate into specific tissues by inserting a targeted sequence described herein into the capsid protein, for example, between amino acids 588 and 589, into the AAV9 capsid protein VP1.

[0047] An example of the wild-type AAV9 capsid protein VP1 (Q6JC40-1) sequence is as follows:

[0048] [ka]

[0049] Accordingly, provided herein are AAVs comprising one or more of the targeted peptide sequences described herein, for example, a capsid protein comprising a targeted sequence described herein, for example, an AAV comprising a capsid protein comprising SEQ ID NO: 1, wherein the targeted peptide sequence is inserted, for example, between amino acids 588 and 589.

[0050] Immunotherapy Induction Genes In some embodiments, the AAV also includes a transgene sequence (i.e., heterologous sequence) encoding an immunotherapy agent, such as those described herein or known in the art. The transgene is preferably ligated to a sequence that promotes / drives the expression of the transgene in the target tissue.

[0051] Exemplary transgenes for use as immunotherapeutic agents include immune checkpoint inhibitor antibodies or their antigen-binding fragments, such as those encoding single-stranded variable fragment (scFv) antibodies that act as checkpoint inhibitors.

[0052] Examples of immunotherapy include, but are not limited to, adoptive T-cell therapies or cancer vaccine formulations designed to induce T lymphocytes to recognize cancer cells, and anti-CD137 antibodies (e.g., BMS-663513), anti-PD1 antibodies (e.g., nivolumab, pembrolizumab / MK-3475, pizilizumab (CT-011)), anti-PDL1 antibodies (e.g., BMS-936559, MPDL3280A), or anti-CTLA-4 antibodies (e.g., ipilumimab; e.g., Kruger et al. (2007) Histol Histopathol. 22(6): 687-96; Eggermont et al. (2010) Semin Oncol. 37(5): 455-9; Klinke (2010) Mol. Cancer. 9: 242; Alexandrescu et al. (2010) J. This includes checkpoint inhibitors such as Immunother. 33(6): 570-90; Moschella et al. (2010) Ann NY Acad Sci. 1194: 169-78; Ganesan and Bakhshi (2010) Natl. Med. J. India 23(1): 21-7; and Golovina and Vonderheide (2010) Cancer J. 16(4): 342-7.

[0053] Exemplary anti-PD-1 antibodies that may be used in the methods described herein include those that bind to human PD-1, and exemplary PD-1 protein sequences are provided under NCBI accession number NP_005009.2. Exemplary antibodies are described in U.S. Patent No. 8,008,449; U.S. Patent No. 9,073,994; and U.S. Patent Application Publication No. 2011 / 0271358, and include, for example, PF-06801591, AMP-224, BGB-A317, BI754091, JS001, MEDI0680, PDR001, REGN2810, SHR-1210, TSR-042, pembrolizumab, nivolumab, avelumab, semiprimab, spartalizumab, camrelizumab, cintilimab, pizilizumab, tislerizumab, tripalimab, AMP-224, AMP-514, and atezolizumab.

[0054] Exemplary anti-CD40 antibodies that may be used in the methods described herein include those that bind to human CD40, and exemplary CD40 protein precursor sequences are provided under NCBI accession numbers NP_001241.1, NP_690593.1, NP_001309351.1, NP_001309350.1 and NP_001289682.1. Exemplary antibodies include those described in International Publication No. 2002 / 088186; International Publication No. 2007 / 124299; International Publication No. 2011 / 123489; International Publication No. 2012 / 149356; International Publication No. 2012 / 111762; International Publication No. 2014 / 070934; U.S. Patent Application Publication No. 2013 / 0011405; U.S. Patent Application Publication No. 2007 / 0148163; U.S. Patent Application Publication No. 2004 / 0120948; U.S. Patent Application Publication No. 2003 / 0165499; and U.S. Patent No. 8,591,900, such as dasetuzumab, lucatumumab, breserumab, teneriximab, ADC-1013, CP-870, 893, Chi Lob This includes 7 / 4, HCD122, SGN-4, SEA-CD40, BMS-986004, and APX005M. In some embodiments, the anti-CD40 antibody is a CD40 agonist and not a CD40 antagonist.

[0055] Exemplary anti-PD-L1 antibodies that may be used in the methods described herein include those that bind to human PD-L1, and exemplary PD-L1 protein sequences are provided in NCBI accession numbers NP_001254635.1, NP_001300958.1, and NP_054862.1. Exemplary antibodies are described in U.S. Patent Application Publication No. 2017 / 0058033; International Publication No. 2017 / 118321A1; International Publication No. 2016 / 061142A1; International Publication No. 2016 / 007235A1; International Publication No. 2014 / 195852A1; and International Publication No. 2013 / 079174A1, for example, BMS-9365 These include 59 (MDX-1105), FAZ053, KN035, atezolizumab (Tecentriq, MPDL3280A), avelumab (Bavencio), durvalumab (Imfinzi, MEDI-4736), emvafolimab (KN035), CK-301, CS-1001, SHR-1316 (HTI-1088), CBT-502 (TQB-2450), BGB-A333, and BMS-986189. Non-antibody peptide inhibitors, such as AUNP12 and CA-170, may also be used. See also Akinleye & Rasool, Journal of Hematology & Oncology 12:92 (2019) doi:10.1186 / s13045-019-0779-5.

[0056] In some embodiments, the immunotherapy agent is or comprises an antigen-binding moiety of an anti-PD-L1 antibody, for example, a single-strand variable fragment (scFv) antibody against the human PD-L1 protein (PD-L1.Hu), and an exemplary sequence encoding an anti-PD-L1 antibody scFv is shown in SEQ ID NO: 105, or, for example, a portion thereof lacking one, two or more signal peptides, HA-tags, and Myc-tags, and including, for example, amino acids (aa) 31-513 of SEQ ID NO: 105.

[0057] Exemplary anti-PDL1 scFv sequences (signal peptides (aa1~21); HA-tags, aa21~30; Myc-tags, aa514~523)

[0058] [ka]

[0059] The following are exemplary anti-PD-L1 nucleic acid sequences (signal peptides (nt1~63); HA-tags, nt64~90; Myc-tags, nt1540~1569).

[0060] [ka]

[0061] Other antibodies and methods for producing nucleic acids encoding such antibodies are known in the art; see, for example, Li et al., Int J Mol Sci. 2016 Jul; 17(7): 1151; Engeland et al., Mol Ther. 2014 Nov; 22(11): 1949-1959, and the references above.

[0062] The virus may also include one or more sequences that promote the expression of the transgene, e.g., one or more promoter sequences; enhancer sequences, e.g., a 5' untranslated region (UTR) or 3'UTR; a polyadenylation site; and / or an insulator sequence. In some embodiments, the promoter is a brain tissue-specific promoter, e.g., a neuron-specific or glial-specific promoter. In certain embodiments, the promoter is a promoter of a gene selected from nucleus (NeuN), glial fibrillary acidic protein (GFAP), MeCP2, adenomatous polyposis (APC), ionized calcium-binding adapter molecule 1 (Iba-1), synapsin I (SYN), calcium / calmodulin-dependent protein kinase II, tubulin alpha I, neuron-specific enolase, and platelet-derived growth factor beta chain. In some embodiments, the promoter is a pancellular promoter, e.g., a cytomegalovirus (CMV), beta-glucuronidase (GUSB), ubiquitin C (UBC), or Roussarcoma virus (RSV) promoter. Woodchuck hepatitis virus post-transcriptional response elements (WPREs) may also be used. In some embodiments, human signal or leader sequences, such as IgK leader sequences, are used. In some embodiments, human signal sequences are used instead, as shown in the table below (the table was edited from novoprolabs.com / support / articles / commonly-used-leader-peptide-sequences-for-efficient-secretion-of-a-recombinant-protein-expressed-in-mammalian-cells-201804211337.html).

[0063] [Table 2]

[0064] In some embodiments, secretory sequences that promote antibody secretion are used, for example, as described in von Heijne, J Mol Biol. 1985 Jul 5;184(1):99-105; Kober et al., Biotechnol. Bioeng. 2013; 110: 1164-1173; Tsuchiya et al., Nucleic Acids Research Supplenzent No. 3 261-262 (2003).

[0065] In some embodiments, AAV also has one or more further mutations that increase delivery to target tissues, e.g., CNS, or reduce off-targeting to tissues, e.g., mutations that decrease liver delivery if CNS, cardiac, or muscle delivery is intended (e.g., described in Pulicherla et al. (2011) Mol Ther 19:1070-078); or additional targeted peptides, e.g., Chen et al. (2008) Nat Med 15:1215-1218 or Xu et al., (2005) Virology 341:203-214 or U.S. Patent No. 9,102,949; U.S. Patent No. 9,585,971; and U.S. Patent Application Publication No. 2017,016,6926. See also Gray and Samulski (2011) “Vector design and considerations for CNS applications,” in Gene Vector Design and Application to Treat Nervous System Disorders ed. Glorioso J., editor. (Washington, DC: Society for Neuroscience;) 1-9, available at sfn.org / ~ / media / SfN / Documents / Short%20Courses / 2011%20Short%20Course%20I / 2011_SC1_Gray.ashx.

[0066] How to use The methods and compositions described herein may be used to deliver immunotherapy compositions to tissues, such as the central nervous system (brain), heart, muscle, or dorsal root ganglia or spinal cord (peripheral nervous system). In some embodiments, the methods include delivery to specific brain regions, such as the cerebral cortex, cerebellum, hippocampus, substantia nigra, or amygdala. In some embodiments, the methods include delivery to neurons, astrocytes, and / or glial cells.

[0067] In some embodiments, methods and compositions, such as AAV, are used to deliver nucleic acid sequences encoding an immunotherapy agent to subjects having brain tumors. Brain tumors include gliomas (e.g., glioblastoma multiforme (GBM)), metastases (e.g., from lung cancer, breast cancer, melanoma, or colon cancer), meningiomas, pituitary adenomas, and acoustic neuromas. Accordingly, a method may include administering systemically, for example intravenously, an AAV (e.g., AAV9) (e.g., AAV.CPP16, with CPP16 inserted, also referred to herein as AAV.CPP16) encoding an immunotherapy agent, comprising the targeted peptide described herein, to a subject diagnosed with a brain tumor.

[0068] In some embodiments, the method also includes the co-administration of a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is a toxic or cytotoxic drug, including, but not limited to, temozolamide, lomustine, or a combination thereof. See, for example, Herrlinger et al., Lancet. 2019 Feb 16;393(10172):678-688. The method may also include the administration of radiation, surgical resection, or both.

[0069] Pharmaceutical composition and method of administration The methods described herein include the use of a pharmaceutical composition comprising (i) a targeted peptide and (ii) an AAV containing a sequence encoding an immunotherapy agent as an active ingredient.

[0070] Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable carrier” includes saline, solvents, dispersions, coatings, antimicrobial and antifungal agents, isotonic agents and absorption retarders, etc., that are compatible with the pharmaceutical administration.

[0071] Pharmaceutical compositions are typically formulated to suit their intended route of administration. Examples of routes of administration include parenteral administration, such as intravenous, intra-arterial, subcutaneous, intraperitoneal, intramuscular, or injection or infusion. Therefore, delivery may be systemic or topical.

[0072] Methods for formulating appropriate pharmaceutical compositions are publicly known in the art; see, for example, Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, a solution or suspension used for parenteral administration may contain the following components: sterile diluents such as water for injection, saline, non-volatile oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates; and isotonic modifiers such as sodium chloride or dextrose. The pH can be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral formulations can be sealed in ampoules, disposable syringes, or multi-dose vials made of glass or plastic.

[0073] Pharmaceutical compositions suitable for injection may include sterile aqueous solutions (if water-soluble) or dispersions, and sterile powders for the immediate preparation of sterile injection solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and should be fluid insofar as it is readily injectable. It should be stable under manufacturing and storage conditions and protected against microbial contamination, such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Inhibition of microbial action can be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferable to include isotonic agents, such as sugars, polyhydric alcohols like mannitol and sorbitol, and sodium chloride in the composition. Sustained absorption of the injectable composition can be achieved by including absorption retarders, such as aluminum monostearate and gelatin, in the composition.

[0074] Sterile injection solutions can be prepared by incorporating the required amount of the active compound into a suitable solvent containing one or a combination of the components listed above, as needed, followed by sterile filtration. Generally, dispersion systems are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. For sterile powders for preparing sterile injection solutions, preferred preparation methods are vacuum drying and freeze-drying, which yield powders of any further desired components in addition to the active ingredient from the previously sterile-filtered solution.

[0075] In one embodiment, the therapeutic compound is prepared on a carrier that protects the therapeutic compound from rapid elimination from the body, such as a controlled-release formulation, including implants and microencapsulation delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyacid anhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Such formulations can be prepared using standard techniques or are commercially available, for example, from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions (containing liposomes targeting cells selected by monoclonal antibodies against cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared, for example, according to methods known to those skilled in the art, as described in U.S. Patent No. 4,522,811.

[0076] The pharmaceutical composition may be included in a kit, container, pack, or dispenser along with instructions for administration. [Examples]

[0077] The present invention is further described in the following embodiments, which do not limit the scope of the invention as described in the claims.

[0078] material and method The following materials and methods were used in the following examples.

[0079] 1. Generation of capsid variants To generate capsid variant plasmids, DNA fragments encoding cell-permeable peptides (Table 3) were synthesized (GenScript) and inserted into the backbone of the AAV9 Rep-cap plasmid (pRC9) between amino acid positions 588 and 589 (VPA amino acid numbering) using CloneEZ seamless cloning technology (GenScript). CPP BIP1 (VPALR, SEQ ID NO: 1) and BIP2 (VSALK, SEQ ID NO: 2), as well as their derivatives, e.g., TVSALK in AAV.CPP.16 (SEQ ID NO: 4) and TVSALFK in AAV.CPP.21 (SEQ ID NO: 8), are derived from the Ku70 protein, and their sequences are provided below:

[0080] [ka]

[0081] Furthermore, the VP1 protein sequences for AAV9, AAV.CPP.16, and AAV.CPP.21 are provided below:

[0082] [ka]

[0083] [ka]

[0084] 2. Manufacturing of recombinant AAV Recombinant AAV was packaged using a standard three-plasmid co-transfection protocol (pRC plasmid, p helper plasmid, and pAAV plasmid). pRC9 (or its variants) containing the transgene (e.g., nucleus-directed RFP H2B-mCherry driven by a ubiquitous EF1a promoter), p helper, and pAAV were co-transfected into HEK 293T cells using polyethyleneimine (PEI, Polysciences). The rAAV vector was recovered from serum-free medium 72 and 120 hours after transfection, and from cells 120 hours after transfection. AAV particles in this medium were concentrated using PEG precipitation with 8% PEG-8000 (mG / volume). The cell pellet containing the virus particles was resuspended and lysed by sonication. Viral vectors, combined from PEG precipitate and cell lysates, were treated with DNase and RNase at 37°C for 30 minutes, and then purified by iodixanol gradients (15%, 25%, 40%, and 60%) using ultracentrifugation (VTi 50 rotor, 40,000 rpm, 18°C, 1 hour). rAAV was then concentrated using a Millipore Amicon filter unit (UFC910008, 100K MWCO) and formulated in Dulbecco phosphate-buffered saline (PBS) containing 0.001% Pluronic F68 (Gibco).

[0085] 3.AAV titration Viral titers were determined by measuring DNase-resistant genome copies using quantitative PCR. pAAV-CAG-GFP was digested with PVIII(NEB) to generate free ends for plasmid ITRs, which were used to generate standard curves. Viral samples were incubated with DNase I to remove contaminating DNA, followed by sodium hydroxide treatment to lyse the viral capsid and release the viral genome. Quantitative PCR was performed using ITR forward primer 5'-GGAACCCCTAGTGATGGAGTT (SEQ ID NO: 91) and ITR reverse primer 5'-CGGCCTCAGTGAGCGA (SEQ ID NO: 92). Vector titers were normalized against the rAAV-2 reference standard (RSM, ATCC, catalog number: VR-1616, Manassas, VA).

[0086] 4. Administration of AAV in mice For intravenous administration, AAV diluted with sterile saline (0.2 ml) was administered by tail vein injection to adult mice (over 6 weeks old). The animals were then kept alive for 3 weeks before being euthanized and tissue samples collected. For intracerebral injection, AAV diluted with PBS (10 ul) was injected using a Hamilton syringe at a location 1.0 mm to the right, 0.3 mm posterior, and 2.6 mm deep from the cruciate suture. All animal experiments were conducted at an AAALAC-accredited facility approved by IACUC.

[0087] 5. Processing of mouse tissue Anesthetized animals were perfused intracardiacly with cold phosphate-buffered saline (PBS), followed by intracardiac perfusion with 4% paraformaldehyde (PFA). Tissue was post-fixed overnight with 4% PFA, then immersed in 30% sucrose solution for two days, and finally embedded in an OCT scanner and snap-frozen. Typically, 80 μm thick brain sections were cut for spontaneous fluorescence imaging, and 40 μm thick brain sections were cut for intravascular coherence (IHC).

[0088] 6. In vitro human BBB spheroid model Hot 1% agarose (50 µg / volume) was placed in a 96-well plate and cooled / solidified. Primary human astrocytes (Lonza Bioscience), human brain microvascular pericytes (HBVP, ScienCell Research Laboratories), and human brain microvascular endothelial cells (hCMEC / D3; Cedarlane) were then seeded onto this agarose gel in a 1:1:1 ratio (1500 cells of each type). The cells were cultured at 37°C in a 5% CO2 incubator for 48–72 hours to allow for the spontaneous construction of multicellular BBB spheroids. It was reported that a multicellular barrier mimicking the BBB was formed around these spheroids. AAV-H2B-mCherry was added to this culture medium, and after 4 days, all spheroids were fixed with 4% PFA, transferred to Nunc Lab-Tek II thin glass 8-well chamber coverslips (Thermo Scientific), and imaged using a Zeiss LSM710 confocal microscope. The intensity of the RFP signal within these spheroids was examined and used as a "readout".

[0089] 7. AAV administration in non-human primates (NHPs) All NHP tests were performed by a CRO at an AAALAC-accredited facility approved by IACUC. Cynomolgus monkeys were pre-screened for near-absence or absence of neutralizing antibodies against AAV9 (<1:5 titer). AAV diluted in PBS / 0.001% F68 was administered intravenously using a peristaltic pump (via the cephalic or femoral vein). Three weeks later, the animals were perfused transcardially with PBS, followed by transcardial perfusion with 4% PFA. Tissue was then collected and processed for paraffin embedding and sectioning.

[0090] 8. Immunohistochemistry Mouse tissue sections were stained using floating staining with primary antibodies diluted in PBS containing 10% donkey serum and 2% Triton X-100. Primary antibodies used included chicken anti-GFP (1:1000), rabbit anti-RFP (1:1000), mouse anti-NeuN (1:500), rat anti-GFAP (1:500), goat anti-GFAP (1:500), and mouse anti-CD31 (1:500). Secondary antibodies conjugated to Alexa Fluor 488, Alexa Fluor 555, or Alexa Fluor 647 fluorophores were applied at a 1:200 dilution against the host species of the primary antibody.

[0091] In the case of paraffin sections of NHP tissue, DAB staining was performed to visualize cells transduced by AAV-AADC. Rabbit anti-AADC antibody (1:500, Millipore) was used as the primary antibody.

[0092] 9. AAV binding assay HEK293T cells were cultured at 37°C in a 5% CO2 incubator. One day after seeding HEK293T cells into a 24-well plate at a density of 250,000 cells per well, these cells were transiently transfected with the LY6A cDNA plasmid using a transfection mixture of 200 μl DMEM (31053028; Gibco), 1 μg DNA plasmid, and 3 μg PEI. Forty-eight hours after transfection, the cells were cooled on ice for 10 minutes. The medium was then replaced with 500 μl ice-cold serum-free DMEM medium containing rAAV-mCherry at an MOI of 10,000. After incubation on ice for one hour, cells, presumably with AAV bound to the surface, were washed three times with cold PBS, and then genomic DNA was isolated. The viral particles bound to cells were quantified using qPCR with mCherry-specific primers and normalized to the HEK293T genome using human GCG as a reference.

[0093] 10. Mouse model of glioblastoma All experiments were conducted at Brigham and Women's Hospital and Harvard Medical School according to protocols approved by the Animal Care and Use Committees (IACUC). Syngeneic immune-responsive C57BL / 6 female mice weighing 20+ / -1g (Envigo) were used. GL261-Luc (100,000 mouse glioblastoma cells) resuspended in 2 μl of phosphate-buffered saline (PBS) was injected intracranially using a 10 μl syringe equipped with a 26-gauge needle (80075; Hamilton). The transplantation site was positioned using a stereotactic frame (coordinates from the cruciate suture (mm): 2 right, 0.5 anterior, and 3.5 depth into the cerebral cortex). Seven days later, a single dose of 200 μl of AAV-HSV-TK1 (1E+12 viral genomes, IV) was administered, followed by daily administration of ganciclovir (50 mg / kg) for 10 days.

[0094] [Example 1] AAV9 Capsid Modification AAV peptide display technology was used to identify peptide sequences that would enhance the penetration of biomolecules or viruses across the blood-brain barrier. Individual cell-permeable peptides, listed in Table 3, were inserted into the AAV9 capsid between amino acids 588 and 589 (VP1 numbered), as illustrated in Figure 1A. This insertion was performed by modifying the RC plasmid, one of three plasmids co-transfected for AAV packaging; Figure 1B shows an exemplary schematic diagram of this experiment. Individual AAV variants were fabricated and screened separately. For further details, see Materials and Methods #1–3.

[0095] [Table 3]

[0096] [Example 2] First round of in vivo screening AAVs expressing nuclear RFP (H2B-RFP) were intravenously injected into adult mice with mixed C57BL / 6 and BALB / c gene backgrounds. Three weeks later, brain tissue was collected and sectioned to identify RFP-labeled cells (white dots in Figures 2A and 2C, quantified in Figures 2B and 2D, respectively). CPP BIP1 and BIP2 were inserted into the capsids of AAV.CPP.11 and AAV.CPP.12, respectively. For further details, see Materials and Methods #4-5.

[0097] [Example 3] Optimization of modified AAV9 capsids AAV.CPP.11 and AAV.CPP.12 were further manipulated by optimizing the BIP targeting sequence. The BIP insert was derived from the protein Ku70 (see Figure 3A and Materials / Methods #1 for the complete sequence). The BIP sequence VSALK, of "synthetic" origin, was selected as the study focus to minimize the potential species specificity of the manipulated AAV vector. The AAVs were fabricated and separately tested for brain transduction efficiency compared to AAV9 (see Figures 3B-C). The rate of cellular transduction in mouse liver 3 weeks after IV injection of several AAV variants delivering the reporter gene RFP is shown in Figure 3D. See Materials and Methods #1-5 for further details.

[0098] [Example 4] In vitro model - BBB penetrant screening A subset of AAV variants were screened for their ability to transcend human BBB using an in vitro spheroid BBB model. This spheroid contains human microvascular endothelial cells, human pericytes, and astrocytes that form a barrier on their surface. AAVs with nuclear RFP as reporters were evaluated for their ability to permeate from the surrounding culture medium into the interior of this spheroid and transduce cells within. Figure 4A shows an overview of the experiment. Figures 4B–D show the results for wt AAV9, AAV.CPP.16, and AAV.CPP.21, respectively, and these and other peptides are quantified in Figure 4E. In this model, peptides 11, 15, 16, and 21 caused the greatest penetration into the spheroid. For further details, see Materials and Methods #6.

[0099] [Example 5] In vivo blood-brain barrier penetration screening In the experiment conducted as described above for Example 2, AAV.CPP.16 and AAV.CPP.21 were selected for further evaluation in an in vivo model. All AAVs had nuclear RFP as a reporter. Both showed enhanced ability to transduce brain cells after intravenous administration compared to AAV9 in adult C57BL / 6J mice (white dots in brain sections in Figure 5A, quantified in Figure 5B) and adult BALB / c mice (white dots in brain sections in Figure 6A, quantified in Figure 6B).

[0100] High doses of AAV.CPP.16 and AAV.CPP.21 (4 x 10 per mouse) 12 Vacuum (vg, IV administration) induced widespread brain phenotype in mice. Both AAVs possessed nuclear RFP as reporters (white dots in brain sections in Figure 7A, quantified in Figure 7B).

[0101] [Example 6] Distribution of modified AAV in human beings As shown in Figure 8A, AAV.CPP.16 and AAV.CPP.21 preferentially targeted neurons (labeled with NeuN antibody) across multiple brain regions in mice, including the cerebral cortex, midbrain, and hippocampus. Both AAVs had nuclear RFP as a reporter.

[0102] AAV.CPP.16 and AAV.CPP.21 also showed enhanced ability compared to AAV9 in targeting spinal cord and motor neurons in mice. All AAVs had nuclear RFP as a reporter and were administered intravenously to neonatal mice (4×10 10 vg). Motor neurons were visualized using CHAT antibody staining. Co-localization of the RFP signal and CHAT signal in Figure 8B suggested specific transduction of motor neurons.

[0103] The relative ability of AAV-CAG-H2B-RFP and AAV.CPP.16-CAG-H2B-RFP to transduce various tissues in mice was also evaluated. 1×10 11 vg was injected intravenously. The number of transduced cells was normalized to the number of total cells labeled by DAPI nuclear staining. This result showed that AAV.CPP.16 was more efficient than AAV9 in targeting heart tissue (Figure 9A); skeletal muscle tissue (Figure 9B), and dorsal root ganglion tissue (Figure 9C) in mice.

[0104] [Example 7] BBB Penetration in Non-Human Primate Models 2×10 13AAVs-CAG-AADC (as a reporter gene) at a dose of vg / kg was intravenously injected into 3-month-old cynomolgus monkeys. AAV-transduced cells (shown in black) were visualized using antibody staining against AADC. As shown in Figures 10A–D, AAV.CPP.16 and AAV.CPP.21 showed enhanced ability to transduce into brain tissue after intravenous administration in non-human primates compared to AAV9. AAV.CPP.16 transduced significantly more cells in the primary visual cortex (Figure 10A), parietal cortex (Figure 10B), thalamus (Figure 10C), and cerebellum (Figure 10D) compared to wt AAV9. For further details, see Materials and Methods #7–8.

[0105] [Example 8] AAV.CPP.16 and AAV.CPP.21 do not bind to LY6A. LY6A functions as a receptor for AAV.PHP.eB and mediates the robust effect of AAV.PHP.eB across BBB in certain mouse strains. Overexpression of mouse LY6A in 293 cultured cells significantly increased AAV.PHP.eB binding to the cell surface (see Figure 11A). Conversely, overexpression of LY6A did not increase viral binding to AAV9, AAV.CPP.16, or AAV.CPP.21 (see Figure 11B). This suggests that AAV.CPP.16 or AAV.CPP.21 do not share LY6A as a receptor with AAV.PHP.eB. For further details, see Materials and Methods #9.

[0106] [Example 9] Delivery of therapeutic proteins to the brain using AAV.CPP.21 We used AAV.CPP.21 to systemically deliver the “suicide gene” HSV.TK1 in a mouse model of brain tumor (Materials and Methods #10). HSV.TK1 converts ganciclovir, which is otherwise “dormant,” into a tumor killer. Intravenously administered AAV.CPP.21-H2BmCherry (Figure 12A, lower left and center right panels) was shown to target the tumor, particularly the tumor's spreading frontier. As shown in Figures 12B-C, the use of AAV.CPP.21 for systemic delivery of the “suicide gene” HSV.TK1, when combined with the prodrug ganciclovir, resulted in brain tumor reduction. These results demonstrate that therapeutic genes can be systemically delivered to brain tumors using AAV.CPP.21. For further details, see Materials and Methods #10.

[0107] [Example 10] Intracerebral administration of AAV.CPP.21 In addition to systemic administration (e.g., in Example 2), the AAVs described herein were administered topically to the mouse brains. Intracerebral injection of AAV9-H2B-RFP and AAV.CPP.21-H2B-RFP (Figure 13) induced broad and high-intensity RFP signals in brain sections treated with AAV.CPP.21 compared to brain sections treated with AAV9. For further details, see Materials and Methods #4.

[0108] [Example 11] Systemic delivery of AAV.CPP.16 to the glioblastoma tumor microenvironment Using systemic administration (e.g., in Example 2), the AAVs described herein were delivered to the brains of an orthotopic immune-responsive mouse glioblastoma model (GL261 model) (as described in Materials and Methods #10). As shown in Figure 14, AAV.CRP16 far outperformed AAV9 in terms of significant delivery to both the tumor and the surrounding microenvironment.

[0109] To determine whether this increased delivery efficiency leads to improved therapeutic efficacy, various treatments were administered to a mouse GBM model. Figure 15A provides an overview of the experimental protocol. The results are shown in Figures 15B-C, demonstrating that AAV.CPP.16 anti-PD-L1 mediated immunotherapy significantly extended the survival time of the mouse GBM model. As shown in Figure 15B, one out of eight mice treated with AAV9 anti-PD-L1 survived for an extended period, while six out of eight mice treated with AAV.CPP.16 anti-PD-L1 survived for an extended period (longer than 100 days). Figure 15C shows that all six of the extended survivors (five treated with AAV.CPP.16 anti-PD-L1 and one treated with AAV9 anti-PD-L1; one of the extended survivors treated with AAV.CPP.16 anti-PD-L1 died during a re-challenge surgery for technical reasons) were still alive 200 days after tumor transplantation. Therefore, intravenous injection of AAV.CPP.16 expressing an antibody targeting mouse PD-L1 eradicated GBM tumors in 75% of mice, while untreated mice died within one month of tumor transplantation.

[0110] Long-lived mice were sacrificed on day 200, and their brains were examined. As shown in Figure 16A, no evidence of tumor was present. Figure 16B shows a bioluminescence image taken from one of the mice with extended survival time, indicating the presence of tumor cells 7 days after transplantation. Figure 16C shows that the initial tumor transplant lacked residual tumor and only gliosis scar tissue was present, indicating complete tumor eradication.

[0111] Furthermore, immunohistochemistry revealed the presence of CB8+ cytotoxic T cells in GBM tumor sites, providing further evidence for the immune response.

[0112] [Example 12] Expression of HA-tagged anti-PD-L1 antibodies in GBM tumors Figures 17A-17B show the expression of HA-tagged anti-PD-L1 antibodies in GBM tumors as measured by Western blotting. Five days after tumor transplantation in mice, 1 e12 vg of AAV or PBS was intravenously injected. Tumor tissue was collected 14 days after IV injection. The intensity of HA tag staining (Figure 17A) was quantified as a measure of anti-PD-L1 antibody expression (Figure 17B).

[0113] References

[0114] [Table 4-1]

[0115] [Table 4-2]

[0116] Other Embodiments Although the present invention is described in conjunction with its detailed description, it should be understood that the above description is intended to illustrate, and not to limit, the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the claims below. The inventions described in the original claims are listed below. [Invention 1] A method for delivering an immunotherapy agent to cancer in a subject, comprising the steps of administering to the subject an adeno-associated virus (AAV) comprising (i) a capsid protein comprising an amino acid sequence containing at least four consecutive amino acids from the sequence TVSALFK (SEQ ID NO: 8); TVSALK (SEQ ID NO: 4); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84), and (ii) a transgene encoding an immunotherapy agent, wherein the cancer cells are optionally present in the brain of the human subject. [Invention 2] The method according to Invention 1, wherein the amino acid sequence comprises at least five consecutive amino acids from the sequence TVSALK (SEQ ID NO: 4); TVSALFK (SEQ ID NO: 8); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84). [Invention 3] The method according to Invention 1, wherein the amino acid sequence comprises at least six consecutive amino acids from the sequence TVSALK (SEQ ID NO: 4); TVSALFK (SEQ ID NO: 8); KLASVT (SEQ ID NO: 83); or KFLASVT (SEQ ID NO: 84). [Invention 4] A method for delivering an immunotherapy agent to cancer in a subject, comprising the steps of: (i) administering an adeno-associated virus (AAV) to the subject, comprising an amino acid sequence comprising at least four consecutive amino acids from sequence V[S / p][A / m / t / ]L (SEQ ID NO: 79), TV[S / p][A / m / t / ]L (SEQ ID NO: 80), TV[S / p][A / m / t / ]LK (SEQ ID NO: 81), or TV[S / p][A / m / t / ]LFK (SEQ ID NO: 82), and (ii) a transgene encoding an immunotherapy agent, wherein the cancer cells are optionally present in the brain of the human subject. [Invention 5] The method according to Invention 4, wherein the targeting sequence includes VPALR (SEQ ID NO: 1); VSALK (SEQ ID NO: 2); TVPALR (SEQ ID NO: 3); TVSALK (SEQ ID NO: 4); TVPMLK (SEQ ID NO: 12); TVPTLK (SEQ ID NO: 13); FTVSALK (SEQ ID NO: 5); LTVSALK (SEQ ID NO: 6); TVSALFK (SEQ ID NO: 8); TVPALFR (SEQ ID NO: 9); TVPMLFK (SEQ ID NO: 10) or TVPTLFK (SEQ ID NO: 11). [Invention 6] The method according to any one of inventions 1 to 5, wherein the transgene encoding the immunotherapy agent encodes an antibody that targets PD-1 or PD-L1. [Invention 7] The method according to Invention 6, wherein the subject is a mammal. [Invention 8] The method according to Invention 7, wherein the AAV is AAV9. [Invention 9] The method according to Invention 8, wherein the AAV9 includes AAV9 VP1. [Invention 10] The method according to Invention 9, wherein the targeting sequence is inserted at positions corresponding to amino acids 588 and 589 of AAV9 VP1, including SEQ ID NO: 85. [Invention 11] The method according to Invention 7, wherein the cells are located in the brain of the subject, and the AAV is administered by parenteral delivery, intracerebral delivery, or intrathecal delivery. [Invention 12] The method according to Invention 11, wherein the parenteral delivery is by intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular delivery. [Invention 13] The method according to Invention 12, wherein the intrathecal delivery is by lumbar injection, cisterna magna injection, or intraparenchymal injection. [Invention 14] The method according to any one of inventions 1 to 13, further comprising the step of administering a chemotherapeutic agent, radiation, and / or surgical resection to the subject. [Invention 15] The method according to Invention 14, wherein the chemotherapeutic agent comprises temozolamide, lomustine, or a combination thereof.

Claims

1. A pharmaceutical composition for use in a method of delivering an immunotherapy agent to cancer in a target, wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) comprising (i) a capsid protein containing a peptide insert of TVSALFK (SEQ ID NO: 8) or TVSALFK (SEQ ID NO: 4), and (ii) a transgene encoding an immunotherapy agent.

2. The pharmaceutical composition according to claim 1, wherein the transgene encoding the immunotherapy agent encodes an antibody that targets PD-1 or PD-L1.

3. The pharmaceutical composition according to claim 1 or 2, wherein the subject is a mammal.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the AAV is AAV9.

5. The pharmaceutical composition according to claim 4, wherein the AAV9 comprises AAV9 VP1.

6. The pharmaceutical composition according to claim 5, wherein the peptide insert is inserted at positions corresponding to amino acids 588 and 589 of AAV9 VP1 containing SEQ ID NO:

85.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the cancer is located in the brain of the subject.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the AAV is used to be administered by parenteral delivery, intracerebral delivery, or intrathecal delivery.

9. The pharmaceutical composition according to claim 8, wherein the parenteral delivery is by intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular delivery.

10. The pharmaceutical composition according to claim 8, wherein the intrathecal delivery is by lumbar injection, cisterna magna injection, or intraparenchymal injection.

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the method further comprises the step of administering a chemotherapeutic agent, radiation, and / or surgical resection to the subject.

12. The pharmaceutical composition according to claim 11, wherein the chemotherapeutic agent comprises temozolamide, lomustine, or a combination thereof.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the cancer includes glioblastoma.

Images